Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prime Minister's Intervention On Patents And Data Protection Issue Sparks Fresh Row Between Indian And Multinational Drug Makers

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Leading multinational and India drug companies are heading for a veritable face-off over a decision of the prime minister's office to step in for a comprehensive legislative review of contentious statutes related to patent law in India

You may also be interested in...



India’s Supreme Court Reinstates Pfizer’s Sutent Patent, Orders Review For Patent Office

In a new twist, India’s Supreme Court restores Pfizer’s patent for Sutent, but also removes a restraining order that had prevented Cipla from launching a generic copy.

Exclusive: India’s Supreme Court Reinstates Pfizer’s Sutent Patent; Orders Review For Patent Office

In a new twist, India’s Supreme Court restores Pfizer’s patent for Sutent, but also removes a restraining order that had prevented Cipla from launching a generic copy.

Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners

MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal

Related Content

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel